Positive results from early trial of drug that could protect brain cells
Date
News
Date
An international team of researchers have uncovered a biological link that may account for why those with diabetes have a higher risk of developing Parkinson’s.
Date
We’re investing a further £1 million to drive forward drugs that target energy-producing mitochondria to slow the loss of brain cells in Parkinson's.
Date
Parkinson's UK has invested an additional £1 million in NRG Therapeutics Ltd’s mitochondrial drug development programme.
Date
With Lancaster University, we conducted a survey that shows the coronavirus restrictions are having a big impact on the lives and the health of people affected by Parkinson’s.
Date
Parkinson’s UK chose to stay quiet during the recent Black Lives Matter conversations. We believed that by giving others space to have their voices heard, we were playing a role in supporting their message. We were wrong.
Date
A team of researchers at the University of York have shown a protein called Rab10 plays an important role in the loss of brain cells in LRRK2-associated Parkinson’s.
Date
Cannabis-based compounds could be the silver bullet to relieve pain for people with Parkinson’s according to the largest ever study into pain and the condition.
Date
Results from a one-year project, funded through the Parkinson’s Virtual Biotech, suggest that NLX-112 has potential as a future treatment for reducing dyskinesia and improving movement symptoms of Parkinson’s.
Date
Herantis Pharma has published initial results from a phase 1/2 study of an experimental protective protein called CDNF which may hold potential to slow, stop or reverse Parkinson's.
Date
GDNF clinical trial results in 2019 revealed signs that GDNF may make it possible to repair the cells damaged in people with Parkinson’s. We take a look at where we are 1 year later.